Difficult Word/ Phrase | Contextual Sense |
Overwhelming | Very strong; urgently felt |
Emergence | The gradual beginning |
Variant of concern | A variant for which there is evidence of an increase in transmissibility, more severe disease (e.g., increased hospitalizations or deaths), significant reduction in neutralization by antibodies generated during previous infection or vaccination, reduced effectiveness of treatments or vaccines, or diagnostic detection failures |
Adolescent | Being of the age 13 through 19 |
Serosurvey | A sero-survey involves testing of blood serum of a group of individuals and this will be used to monitor trends in prevalence of the novel coronavirus, or SARS-COV-2, infection at the district level |
Immunogenic | relating to or producing an immune response |
Peer-review | The peer-review process subjects an author’s scholarly work, research, or ideas to the scrutiny of others who are experts in the same field (peers) and is considered necessary to ensure academic scientific quality. |
Co-morbidity | (medicine) the coexistence of two or more related medical conditions |
Homologous | Corresponding or similar in position or structure or function or characteristics |
Reliance | The state of relying on something |
Nearly a year after the rollout of COVID-19 vaccines for health-care workers, the primary vaccination schedule to cover 75 million teenagers aged 15-17 years began across the country on January 3. Nearly 0.4 million children received the first dose on the first day. With all adults aged 18 years and above already being covered, the inclusion of teenagers has reduced the eligibility age group to 15 years. The decision to vaccinate teenagers, which was announced by Prime Minister Narendra Modi on December 25 last year, was based on the emergence (The gradual beginning) of the highly transmissive Omicron variant, its spread to many countries in about a month after it was designated as a variant of concern (A variant for which there is evidence of an increase in transmissibility, more severe disease (e.g., increased hospitalizations or deaths), significant reduction in neutralization by antibodies generated during previous infection or vaccination, reduced effectiveness of treatments or vaccines, or diagnostic detection failures), the global case surge, and the trend in many developed countries of vaccinating adolescents (Being of the age 13 through 19) and children. While there is no clear consensus on whether healthy teenagers above 15 should be vaccinated particularly as severe disease and deaths in this age group are relatively low when infected by the virus and a significant percentage of teenagers and children have been already infected as indicated by a few sero surveys (A sero-survey involves testing of blood serum of a group of individuals and this will be used to monitor trends in prevalence of the novel coronavirus, or SARS-COV-2, infection at the district level.), vaccination does increase the level of protection. Unlike in the case of adults who were vaccinated with one of the two vaccines — Covishield or Covaxin — teenagers will be administered only Covaxin. It was found to be safe and immunogenic ( relating to or producing an immune response) in teenagers during a phase-2/3 of the clinical trial; only 175 adolescents aged 12 to 18 years were studied. The data of the trial, yet to be peer-reviewed (The peer-review process subjects an author’s scholarly work, research, or ideas to the scrutiny of others who are experts in the same field (peers) and is considered necessary to ensure academic scientific quality.), were posted on a preprint server on December 29. As in the case of adults, the eligible teenagers will receive the second dose 28 days after the first.
Besides providing teenagers with a primary vaccine, health-care and frontline workers and those above 60 years with co-morbidities ((medicine) the coexistence of two or more related medical conditions) will be provided with a precaution dose. Providing Covaxin as the precaution dose to all the people who have received the same vaccine as part of the primary vaccination schedule, scientifically called as homologous (Corresponding or similar in position or structure or function or characteristics) vaccine booster, will be the best approach at least till there is evidence on using a different vaccine as a booster shot. Though Covaxin accounts for only around 10% of all doses administered till date, the scientific bodies need to factor in vaccine availability too. This becomes particularly important as only Covaxin is used for vaccinating teenagers and its production is very limited in comparison to Covishield. The compulsion to test other vaccines that can be used in place of Covaxin as an additional dose in adults is therefore overwhelming. The approval of two additional vaccines, which are manufactured using different vaccine platforms, will further lessen the reliance (The state of relying on something) on Covaxin for primary vaccination of adults, thus ensuring that the vaccination programme for teenagers does not suffer from shortages midway.
Want to improve your vocabulary further? Download the Lists of Word-Meanings of Previous Months here.
In this blog, we have provided the complete details related to the RRB ALP 2024…
Get the Hindu Editorial Vocabulary for 22th November & discover the toughest words and their…
SBI PO 2024 Notification will be released soon on its official website. Read on to…
The Union Bank LBO Syllabus 2024 has been released on the official website, Candidates can…
Explore our blog "How to Score 50+ Marks in Data Analysis and Interpretation for Union…
Cover all the topics via RRB ALP Study Plan 2024 for CBT 1 exam by…